Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/25265
Title: | Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma |
Authors: | Shamji, MH Sharif, H Layhadi, JA Zhu, R Kishore, U Renz, H |
Keywords: | allergen immunotherapy;antibody response;innate lymphoid cells |
Issue Date: | 29-Jan-2022 |
Publisher: | Elsevier |
Citation: | Shamji, M.H. et al. (2022) 'Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma', Journal of Allergy and Clinical Immunology, 149 (3), pp. 791 - 801. doi: 10.1016/j.jaci.2022.01.016 |
Abstract: | Copyright © 2022 The Authors. Allergen immunotherapy (AIT) is an effective treatment for allergic rhinitis, inducing long-term clinical tolerance to the sensitizing allergen. Clinical tolerance induction can be achieved when AIT is administered for at least 3 years. AIT is associated with the modulation of innate and adaptive immune systems. This comprises inhibition of IgE-dependent activation of mast cells and basophils in the local target organ, suppression of TH2 cells, immune deviation toward TH1 cells, induction of T and B regulatory cells, and production of allergen-neutralizing antibodies. However, recent developments in their underpinning mechanisms have revealed that AIT, administered subcutaneously or sublingually, induces immune regulation through novel cell targets and molecular mechanisms. This comprehensive review discusses how immune tolerance driven by subcutaneous immunotherapy and sublingual immunotherapy is associated with the induction of a novel regulatory subset of innate lymphoid cells and suppression of proinflammatory TH2, allergen-specific TH2 (TH2A), and T follicular helper cells. Moreover, they are associated with exhaustion of TH2A cells and differential expression of nasal and systemic IgA antibodies. Uncovering the underpinning mechanisms of a successful AIT and immune tolerance induction will allow the development of targeted therapeutics for allergic rhinitis with and without asthma. |
URI: | https://bura.brunel.ac.uk/handle/2438/25265 |
DOI: | https//doi.org/10.1016/j.jaci.2022.01.016 |
ISSN: | 0091-6749 |
Appears in Collections: | Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | Copyright © 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology under a Creative Commons license (https://creativecommons.org/licenses/by-nc-nd/4.0/).. | 1.56 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License